The revenue increase was driven by a rise in urologic cancer testing services, which helped offset a decline in solid tumor testing services.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
During an FDA-sponsored workshop last week, participants discussed ideas for a regulatory framework that can evolve with rapidly advancing technology.
Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours.
The technology, called LAMP, produces DNA at a single temperature and at higher amounts than can be achieved with PCR-based amplification.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.
Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.
Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.
Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.